Dihydropyridine Calcium Channel Blockers and Kidney Outcomes.
Matthew F BlumAditya SurapaneniAlexander ChangLesley A InkerTeresa K ChenLawrence J AppelJung-Im ShinMorgan E GramsPublished in: Journal of general internal medicine (2024)
DCCBs were associated with increased risk of albuminuria and, in the absence of RAS blockade, KFRT. These findings suggest coupling DCCB therapy with RAS blockade may mitigate adverse kidney outcomes.